Today: 21 May 2026
Intuit stock rises 2% as ChatGPT apps go live; investors eye jobs data and Feb. 26 earnings
7 February 2026
2 mins read

Intuit stock rises 2% as ChatGPT apps go live; investors eye jobs data and Feb. 26 earnings

New York, February 6, 2026, 21:30 EST — The session wrapped up with markets closed.

  • Intuit finished Friday at $443.77, up 2.04% for the session. Shares remain roughly 45% under their July high.
  • TurboTax, QuickBooks, Credit Karma, and Mailchimp apps from Intuit have landed inside ChatGPT for users in the U.S., the company said.
  • Coming up next week: U.S. jobs and inflation numbers. After that, Intuit’s fiscal Q2 results drop on Feb. 26.

Intuit Inc (INTU) gained 2.04% Friday, finishing the session at $443.77 after buyers snapped up a wide swath of battered software stocks. Trading picked up, with volume topping Intuit’s recent average. Still, shares have a lot of ground to recover—about 45% off the 52-week high from late July.

U.S. markets stay dark until Monday, leaving the focus squarely on the coming economic data. Investors are eyeing Wednesday’s nonfarm payrolls, with Friday’s consumer price index looming right after — both capable of shaking up rate expectations and tech stock pricing in a hurry.

Software stocks aren’t catching a break. The S&P 500 software and services index dropped 4.6% on Thursday and has now erased about $1 trillion in market cap since Jan. 28—a stretch some traders are calling “software-mageddon.” “I would classify this as a sell-everything mindset at this point,” said Dave Harrison Smith, chief investment officer and head of technology investing at Bailard. Reuters

Intuit on Thursday announced that its TurboTax, Credit Karma, QuickBooks, and Mailchimp apps have rolled out inside ChatGPT for U.S. users who are logged in. Chief technology officer Alex Balazs called the move “a new level of trusted guidance and smart financial actions.” Intuit emphasized that customer data remains with Intuit and won’t be used for training foundation models. Intuit

Tax season is in full swing, and that’s crucial for Intuit’s TurboTax business. The IRS kicked off the 2026 filing window back on Jan. 26, with roughly 164 million individual returns projected before the April 15 federal deadline.

Intuit plans to release its fiscal second-quarter 2026 earnings after the bell on Feb. 26, according to the company. Executives are set to host a conference call that day at 1:30 p.m. Pacific. The quarter wrapped up on Jan. 31.

Investors are eyeing whether Intuit’s product tweaks will translate into more reliable payments revenue. This week, the company rolled out a multi-year tie-up with Affirm, making the buy-now, pay-later player the only pay-over-time choice integrated into QuickBooks Payments. “We are giving businesses a powerful new way to increase conversion and improve cash flow,” said David Hahn, an Intuit executive. Intuit Inc.

No consensus yet on just how quickly AI might upend software earnings. “The threat is real and valuations must account for that,” said James St. Aubin, Ocean Park Asset Management’s chief investment officer. That’s been the core driver behind the recent selloff, he noted. Reuters

But it’s not just about sliding stock multiples. Software’s slump is starting to catch up with asset managers and private equity groups, Reuters reported Friday, as investors grow uneasy about loans and leverage linked to the space. “The trigger … is the software selloff and concern over loan exposure and leverage,” said Mark Hackett, Nationwide’s chief market strategist. Reuters

The next event for Intuit stock lands Feb. 26. The company will release its results and face investor questions on tax-season numbers and how quickly its AI products are rolling out.

Stock Market Today

  • Kratos Defense & Security Solutions (KTOS) Stock Valuation: Overvalued After Price Swikes
    May 20, 2026, 8:29 PM EDT. Kratos Defense & Security Solutions (KTOS) has seen significant share price swings, rising 6.3% last week after a 20.1% drop over the past month and a 29.6% decline year-to-date, despite a 62.6% gain over the past year. Recent attention focuses on defense contract wins and program milestones. A Discounted Cash Flow (DCF) analysis indicates KTOS is overvalued by 38.2%, with intrinsic value estimated at $40.39 versus a recent price around $55.82. This suggests the market may be pricing in optimistic growth amid continued free cash flow losses projected through 2027 before turning positive in 2028. Investors should consider these valuation concerns amid price volatility when assessing KTOS stock.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Exxon stock hits a 52-week high — what XOM traders are watching next
Previous Story

Exxon stock hits a 52-week high — what XOM traders are watching next

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week
Next Story

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Go toTop